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In spite of long-te rm prophylaxis with hepatitis B
immune globulin (HBIG), recurrence of hepatitis B
virus (HBV) infection in the graft constitute s the
leading cause of morbidity and mortality among pa-
tients unde rgoing liver transplantation (LT) due to
HBV-induced live r cirrhosis (1). In many of these
patients acce lerated HBV replication overcomes the
protective effect of HBIG (2).
Inte rferon therapy, which is partially effective
against HBV in immunocompetent patients (3), is of
limited value in post-LT HBV graft infection (4).
Lamivudine , a nucleoside analog that inhibits the
reverse transcriptase activity of HBV, has shown
promising results in HBV infection in both immuno-
competent (5) and HIV-immunosuppre ssed patients
(6). Signi® cant improvements in live r histology have
been demonstrated after one year treatment with
lamivudine in immunocompetent patients (7). In-
deed, administration of lamivudine before and after
LT has also been effective in preventing hepatitis B
recurrence after LT (8), and this drug lacks the seri-
ous side effects found with other nucleoside ana-
logues (9).
We report on a LT patient in whom lamivudine
was an effective therapy for acute recurrent HBV
hepatitis.
CASE REPORT
A 48-year-old white man received a liver graft in March
1995 because of HBV liver cirrhosis. Preoperatively, hepa-
titis B surface antigen (HBsAg) and antibodies to the core
and e antigens (anti-HBc and anti-HBe, respective ly) were
detectable in the serum, but hepatitis B e antigen (HBeAg)
and HBV DNA (dot blot) were not detectable. He received
high-dose anti-HBs immunoglobulin, according to Samuel
et al (10) and standard immunosuppression with cyclospor-
ine, azathioprine, and prednisone.
Intraoperative and postoperative courses were unre-
markable, liver function tests became normal within two
weeks after LT, and serum HBsAg became undetectable.
Five months after transplantation he deve loped graft dys-
function secondary to HBV infection. Liver function tests
revealed severe cytolysis and progressively declining hepatic
function (Figure 1). Biliary and vascular complications,
rejection, and other viral infections were ruled out. Liver
biopsy showed lobular hepatitis with marked cholestasis
and the presence of HBsAg and HBcAg in 100% and 60%
of hepatocyte s, respective ly (Figure 2) . Serum HBsAg be-
came detectable and serum HBV DNA leve ls, as deter-
mined by the Digene Hybrid Capture assay (Digene Diag-
nostics, Beltsville, Maryland) were greate r than 2000 pg/ml,
demonstrating accelerated viral replication. Famciclovir
(500 mg every 8 hr) was initiated; HBIG, azathioprine, and
prednisone were discontinued; and the cyclosporine dose
was reduced to maintain blood trough leve ls below 100
ng/ml.
Despite this treatment, liver function tests continued to
worsen, and the patient was switched from famciclovir to
oral lamivudine (100 mg/day). Shortly thereafter, liver func-
tion improved and aminotransferase levels rapidly dimin-
ished, reaching normal levels three months afte r lamivudine
was initiated. Serum HBV DNA leve ls decreased rapidly
and became negative within the ® rst month of lamivudine
therapy. Serum HBsAg remained positive one month after
initiation of lamivudine, but became undetectable two
months later. Aminotransferase values remain within nor-
mal limits and HBV DNA and HBsAg have remained
negative for two years. Six months afte r starting lamivudine,
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the patient was both HBsAg- and anti-HBs-negative , be-
coming anti-HBs-positive six months later; currently, his
serum anti-HBs concentration is 188 mIU/ml. A liver biopsy
performed ® ve months after initiating lamivudine therapy
showed a signi® cant improvement, with only mild to mod-
erate lymphocyte in¯ ammatory activity. Immunostaining
against HBsAg and HBcAg were both negative . This histo-
logical improvement was con® rmed in a second liver biopsy
performed after one year of lamivudine therapy. No ad-
verse event related to this drug was recorded. Currently, the
patient is still on lamivudine and immunosuppressive ther-
apy includes cyclosporine, maintaining trough leve ls at a
range of 50 ± 75 ng/ml.
DISCUSSION
Passive immunoprophylaxis with HBIG reduces
but does not eliminate the risk of recurrent HBV
infection after LT (2). The natural history of HBV
reinfection after LT is usually accelerated because of
immunosuppression. Moreover, some of the patients
develop ® brosing chole static hepatitis, a clinicopath-
ological syndrome characte rized by cholestasis, severe
® brosis, and marked expre ssion of HBV antige ns in
hepatocyte s, which leads to a rapidly progre ssive live r
failure (11) due to a direct cytopathic effect. There is
no effective therapy for this condition. The high viral
replication secondary to immunosuppression makes
inte rferon therapy of limited ef® cacy (4). Adenine
arabinoside monophosphate has shown only a partial
and transient effectiveness (12) and may cause neu-
rotoxicity (13) . Long-te rm therapy with ganciclovir
has been shown to be partially effective in a pilot
study (14) . Although this treatment caused signi® -
cantly reduced HBV DNA in several patients, ALT
value s remained increased in most of them and serum
HBeAg and liver HBsAg remained detectable in all
the patients, demonstrating the inability of ganciclovir
to fully inhibit HBV replication. Furthermore , as its
effect over HBV DNA was transient, ganciclovir had
to be administe red inde ® nite ly. The need for intrave -
nous administration precludes the long-te rm use of
this drug. Recent reports on famciclovir, the oral
form of penciclovir, in the treatment of post-LT HBV
infection has shown only partial activity (15) .
The patient reported in this pape r had a recurrent
HBV infection of the liver graft presenting as a severe
acute hepatitis, with remarkably high viral replication
and progre ssive worsening of liver function. Although
immunosuppression was markedly reduced and fam-
ciclovir was started, live r function deteriorated fur-
ther and viral replication remained extremely high. In
this setting, lamivudine dramatically changed the clin-
ical picture . The patient began to feel better, amino-
transfe rase and bilirubin value s immediate ly de-
creased, and viral replication was fully inhibite d, as
demonstrated by the abrupt fall in serum HBV DNA
leve ls, the rapid loss of serum HBsAg, the persistent
Fig 1. Evolution of serum transaminase (dotted line), bilirubin (solid line), and hepatitis B virus DNA levels (arrowheads) before
and after lamivudine therapy.
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histological improvement, and the loss of HBsAg and
HBcAg in live r tissue .
The effectiveness of lamivudine in this case and in
other preliminary trials warrants furthe r investigation
in the transplant setting and in nontransplant HBV
infection. Pre liminary results from a multicenter trial
of lamivudine after LT have shown promising results
(16) , but several points, such as duration of therapy,
need to be clari® ed because short-term treatment (12
weeks) has only a transient effect on HBV DNA
leve ls (5). Finally, this drug may be useful not only in
chronic infection but also in acute hepatitis B, as
demonstrated by the dramatic improvement of the
patient reported here.
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